Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Gastroesophageal Adenocarcinoma: early-phase trial registry
6 of 9 indexed Gastroesophageal Adenocarcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,916 of 28,707 conditions by registered trial count.
9 US clinical trials · 6 currently recruiting · #1,916 of 28,707 conditions by registered trial count
Gastroesophageal Adenocarcinoma: 9 US clinical trials tracked, 6 recruiting.
Gastroesophageal Adenocarcinoma is the subject of 9 registered US clinical trials on ClinicalTrials.gov, 6 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most active sponsor is Merck Sharp & Dohme, running 2 of these trials.
Enrollment posture brief
Registry condition gastroesophageal-adenocarcinoma
OPEN 6 | RECR 67% | LATE 0 | EARLY 9 | RANK #1916 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Acute Hypoxemic Respiratory Failure (67% recruiting · 6 trials)
Gastroesophageal Adenocarcinoma lists 6 open slots (67% of 9 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Gastroesophageal Adenocarcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Gastroesophageal Adenocarcinoma is recruiting above its size-band peers.
6 of 9 indexed trials (66.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Gastroesophageal Adenocarcinoma research.
Merck Sharp & Dohme accounts for 2 of 9 trials (22.2%). 8 distinct sponsors appear on at least one study for this condition label.
-
Typical Gastroesophageal Adenocarcinoma enrolment sits around 80 participants.
Median target enrolment is 80 among the 9 trials that report a genuine target (sentinel values excluded). 5 of those (55.6%) plan for fewer than 100 participants.
-
Gastroesophageal Adenocarcinoma research is mostly interventional.
9 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
9 total, page 1 of 1
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
Merck Sharp & Dohme
NCT06445972
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
Merck Sharp & Dohme
NCT06469944
A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma
AstraZeneca
NCT07069712
Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels
Yale University
NCT07282912
Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease
Washington University School of Medicine
NCT06529822
Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)
University of California, Irvine
NCT05733689
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab
AbbVie
NCT05029882
Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L)
Weill Medical College of Cornell University
NCT04021108
A Study of a Personalized Neoantigen Cancer Vaccine
Gritstone bio
NCT03639714
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
| Phase 2 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Gastroesophageal Adenocarcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Gastroesophageal Adenocarcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Gastroesophageal Adenocarcinoma page
9 registered trials, 6 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 6 Gastroesophageal Adenocarcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Merck Sharp & Dohme sponsors the most Gastroesophageal Adenocarcinoma trials on record, review their full trial history before evaluating a specific study. See Merck Sharp & Dohme's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Gastroesophageal Adenocarcinoma condition card totals 9 registered trials; most-linked intervention Capecitabine; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.